PKCβ Inhibition Promotes TXNIP Degradation to Ameliorate Pancreatic β-Cell Dysfunction

Area of Science:

• Endocrinology
• Molecular Biology
• Cell Biology

Background:

• TXNIP accumulation is a key regulator of pancreatic beta-cell dysfunction.
• Previous research identified PKA's role in TXNIP degradation, but the involvement of other kinases, like PKCs, remained unclear.

Purpose of the Study:

• To investigate the role of protein kinase Cs (PKCs) in regulating TXNIP levels and their impact on pancreatic beta-cell dysfunction.
• To evaluate the therapeutic potential of PKC inhibitors in ameliorating beta-cell dysfunction.

Main Methods:

• Beta-cell dysfunction was induced using thapsigargin (ER stress inducer).
• PKC inhibitors were screened using Western blotting for TXNIP levels.
• RT-qPCR, co-immunoprecipitation, and glucose-stimulated insulin secretion assays were employed.

Main Results:

• The PKC pan-inhibitor Ro31-8220 reduced beta-cell apoptosis and improved insulin secretion under ER stress and high glucose conditions.
• Ro31-8220 decreased TXNIP levels, while PKCβ activation reversed this effect.
• The PKCβ selective inhibitor, ruboxistaurin, effectively induced TXNIP degradation.

Conclusions:

• This study elucidates the mechanism by which PKCβ inhibitors promote TXNIP degradation, thereby improving beta-cell dysfunction.
• PKCβ inhibitors demonstrate potential as therapeutic agents for ameliorating beta-cell dysfunction via TXNIP modulation.